These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 37776300)

  • 1. Systematic Review and Meta-analysis of Clinical Outcomes After Endovascular Treatment in Patients With Femoropopliteal Lesions Greater Than 150 mm.
    Dubosq-Lebaz M; Fels A; Chatellier G; Gouëffic Y
    J Endovasc Ther; 2023 Sep; ():15266028231202709. PubMed ID: 37776300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stent Graft vs Drug-Coated Balloon in Endovascular Treatment of Complex Femoropopliteal Artery Lesions: A 2-Center Experience.
    Ye M; Ni Q; Zhu Y; Du Y; Wang Y; Guo X; Zhang L; Feng Z
    J Endovasc Ther; 2023 Sep; ():15266028231201097. PubMed ID: 37728023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heparin-bonded covered stents versus bare-metal stents for complex femoropopliteal artery lesions: the randomized VIASTAR trial (Viabahn endoprosthesis with PROPATEN bioactive surface [VIA] versus bare nitinol stent in the treatment of long lesions in superficial femoral artery occlusive disease).
    Lammer J; Zeller T; Hausegger KA; Schaefer PJ; Gschwendtner M; Mueller-Huelsbeck S; Rand T; Funovics M; Wolf F; Rastan A; Gschwandtner M; Puchner S; Ristl R; Schoder M
    J Am Coll Cardiol; 2013 Oct; 62(15):1320-7. PubMed ID: 23831445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endovascular Intervention for the Treatment of Trans-Atlantic Inter-Society Consensus (TASC) D Femoropopliteal Lesions: A Systematic Review and Meta-Analysis.
    Giannopoulos S; Lyden SP; Bisdas T; Micari A; Parikh SA; Jaff MR; Schneider PA; Armstrong EJ
    Cardiovasc Revasc Med; 2021 Jan; 22():52-65. PubMed ID: 32563709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic review and updated meta-analysis of the use of drug-coated balloon angioplasty versus plain old balloon angioplasty for femoropopliteal arterial disease.
    Caradu C; Lakhlifi E; Colacchio EC; Midy D; Bérard X; Poirier M; Ducasse E
    J Vasc Surg; 2019 Sep; 70(3):981-995.e10. PubMed ID: 31126769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. One-year clinical outcome after primary stenting for Trans-Atlantic Inter-Society Consensus (TASC) C and D femoropopliteal lesions (the STELLA "STEnting Long de L'Artère fémorale superficielle" cohort).
    Davaine JM; Azéma L; Guyomarch B; Chaillou P; Costargent A; Patra P; Lambert G; Gouëffic Y
    Eur J Vasc Endovasc Surg; 2012 Oct; 44(4):432-41. PubMed ID: 22920949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stenting for peripheral artery disease of the lower extremities: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2010; 10(18):1-88. PubMed ID: 23074395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-Term Results of Endovascular Treatment with Nitinol Stents for Femoropopliteal TASC II C and D Lesions.
    Kluckner M; Nierlich P; Hitzl W; Aschacher T; Gratl A; Wipper S; Aspalter M; Moussalli H; Linni K; Enzmann FK
    Medicina (Kaunas); 2022 Sep; 58(9):. PubMed ID: 36143902
    [No Abstract]   [Full Text] [Related]  

  • 9. Angioplasty or bare metal stent versus drug-eluting endovascular treatment in femoropopliteal artery disease: a systematic review and meta-analysis.
    Varetto G; Gibello L; Boero M; Frola E; Peretti T; Spalla F; Verzini F; Rispoli P
    J Cardiovasc Surg (Torino); 2019 Oct; 60(5):546-556. PubMed ID: 31527577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug-coated balloons vs. drug-eluting stents for treatment of long femoropopliteal lesions.
    Zeller T; Rastan A; Macharzina R; Tepe G; Kaspar M; Chavarria J; Beschorner U; Schwarzwälder U; Schwarz T; Noory E
    J Endovasc Ther; 2014 Jun; 21(3):359-68. PubMed ID: 24915582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Covered Stents Versus Bare-Metal Stents for Aortoiliac Occlusive Disease: A Systematic Review and Meta-Analysis.
    Hu C; Chen L; Wu M; Ye Q; Zou J; Zhao B; Li X; Wu H
    J Endovasc Ther; 2024 Mar; ():15266028241237387. PubMed ID: 38491926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug Eluting Stent vs. Drug Coated Balloon for Native Femoropopliteal Artery Disease: A Two Centre Experience.
    Lee YJ; Kook H; Ko YG; Yu CW; Joo HJ; Ahn CM; Choi D
    Eur J Vasc Endovasc Surg; 2021 Feb; 61(2):287-295. PubMed ID: 33223281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of a Drug-Eluting Stent Versus Bare Metal Stents for Symptomatic Femoropopliteal Peripheral Artery Disease: Primary Results of the EMINENT Randomized Trial.
    Gouëffic Y; Torsello G; Zeller T; Esposito G; Vermassen F; Hausegger KA; Tepe G; Thieme M; Gschwandtner M; Kahlberg A; Schindewolf M; Sapoval M; Diaz-Cartelle J; Stavroulakis K;
    Circulation; 2022 Nov; 146(21):1564-1576. PubMed ID: 36254728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Single-Center Study on the Outcomes of Target Limb Revascularization in Femoropopliteal Lesions Treated With Drug Coated Balloons and Bare Metal Stents.
    Linehan V; Doyle M; Barrett B; Gullipalli R
    J Endovasc Ther; 2022 Dec; 29(6):948-955. PubMed ID: 34986705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-World Performance of Paclitaxel Drug-Eluting Bare Metal Stenting (Zilver PTX) for the Treatment of Femoropopliteal Occlusive Disease.
    Tran K; Ullery BW; Kret MR; Lee JT
    Ann Vasc Surg; 2017 Jan; 38():90-98. PubMed ID: 27554688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endovascular revascularization strategies for aortoiliac and femoropopliteal artery disease: a meta-analysis.
    Koeckerling D; Raguindin PF; Kastrati L; Bernhard S; Barker J; Quiroga Centeno AC; Raeisi-Dehkordi H; Khatami F; Niehot C; Lejay A; Szeberin Z; Behrendt CA; Nordanstig J; Muka T; Baumgartner I
    Eur Heart J; 2023 Mar; 44(11):935-950. PubMed ID: 36721954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased mortality with paclitaxel-eluting stents is driven by lesion length.
    Mathlouthi A; Yei KS; Naazie I; Bertges DJ; Malas MB
    J Vasc Surg; 2021 Feb; 73(2):548-553.e2. PubMed ID: 32615286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Restenosis Prevention With Drug Eluting or Covered Stents in Femoropopliteal Arterial Occlusive Disease: Evidence From a Comprehensive Network Meta-analysis.
    He R; Ye Y; Li Z; Jiang Y; Li Y; Liu Y; Wang K; Yao C
    Eur J Vasc Endovasc Surg; 2019 Jul; 58(1):61-74. PubMed ID: 31202582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcomes of endovascular treatment of TASC-II C and D femoropopliteal lesions with the Viabahn endoprosthesis.
    Mohr PJ; Oyama JK; Luu JT; Stinis CT
    Cardiovasc Revasc Med; 2015 Dec; 16(8):465-8. PubMed ID: 26483319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative effectiveness of endovascular treatment modalities for de novo femoropopliteal lesions in intermittent claudication: A network meta-analysis of randomized controlled trials.
    Zhou Y; Wang J; He H; Li Q; Li M; Li X; Shu C
    Int J Cardiol; 2021 Nov; 343():122-130. PubMed ID: 34461162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.